The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation
ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study
Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations
Real world outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction
Phase 1b study of Bavdegalutamide, an androgen receptor PROTAC® degrader, combined with abiraterone in patients with metastatic prostate cancer
ARV-471, an estrogen receptor (ER) PROTAC® degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2 negative breast cancer: phase 1b cohort (part C) of a phase 1/2 study
